
Bull’s Eye: Targeted Immunotherapy of Myasthenia Gravis
Myasthenia gravis is a motor disease, starting with muscular pain and potentially escalating to failure of vital muscles such as the diaphragm. Like other autoimmune diseases, it was historically treated with steroids, which suppress the immune system overall. Professor Richard Nowak at the Yale School of Medicine has found a much more targeted attack strategy.